Aerobic Interval vs Continuous Training on Heart Rate-Power Decoupling in Ischemic Heart Disease

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age40-75
SponsorUniversidad Complutense de Madrid

About this trial

This study is a randomized, parallel-group clinical trial with assessor and statistical analyst blinding, conducted at a single center. Participants with stable ischemic heart disease enrolled in a cardiac rehabilitation program will be randomly allocated to one of two aerobic exercise interventions: long extensive continuous aerobic training (zone 2) or long extensive aerobic interval training (zone 3). Both groups will participate in supervised exercise sessions twice weekly for a period of 8 weeks, integrated into the standard cardiac rehabilitation program.

Assessments will be performed at baseline, immediately after the intervention period (8 weeks), and after a 4-week follow-up period without supervised training to evaluate potential detraining effects. The primary outcome is heart rate-power decoupling during a prolonged submaximal cycling exercise test, used as an indicator of cardiovascular efficiency. Secondary outcomes include heart rate response during submaximal exercise, exercise tolerance, heart rate recovery, blood pressure, functional capacity, quality of life, and adherence to the training program.

The objective of this study is to compare the effects of long extensive aerobic interval training versus long extensive continuous training on heart rate-power decoupling and related cardiovascular and functional outcomes in patients with ischemic heart disease undergoing cardiac rehabilitation.

Eligibility criteria

Qualifiers

Confirmed diagnosis of cardiovascular disease requiring cardiac rehabilitation, with medical indication for a supervised exercise training program.

Killip class I or II (absence or mild heart failure)¹.

Absence of recent acute myocardial infarction (< 1 month) or presence of a stable previous infarction.

Stable and well-controlled cardiovascular symptoms.

Disqualifiers

Killip class > III (moderate to severe heart failure).

Recent acute myocardial infarction (< 1 month) with clinical instability.

Active anginal symptoms or decompensated heart failure.

Physical capacity < 5 METs on functional testing, indicating severely reduced exercise capacity.

Trial design

Treatments tested in this trial

  • Intervention Group
  • Control Group (A):

Treatment groups

48 Participants
are divided into 2 treatment groups

Locations

This trial has no locations